Blood Advances (Oct 2019)

BCL2L1 is associated with γ-globin gene expression

  • Yan Dai,
  • Elmutaz M. Shaikho,
  • Jessica Perez,
  • Carolyn A. Wilson,
  • Lesley Y. Liu,
  • Mitchell R. White,
  • John J. Farrell,
  • David H.K. Chui,
  • Paola Sebastiani,
  • Martin H. Steinberg

Journal volume & issue
Vol. 3, no. 20
pp. 2995 – 3001

Abstract

Read online

Abstract: Fetal hemoglobin (HbF) expression is partially governed by the trans-acting quantitative trait loci BCL11A and MYB and a cis-acting locus linked to the HBB gene cluster. Our previous analysis of the Genotype-Tissue Expression database suggested that BCL2L1 was associated with HbF gene expression. In erythroid progenitors from patients with sickle cell disease, BCL2L1 messenger RNA (mRNA) levels were positively correlated with HBG mRNA and total HbF concentration (r 2 = 0.72, P = .047 and r 2 = 0.68, P = .01, respectively). Inhibition of BCL2L1 protein activity in HbF-expressing HUDEP-1 cells decreased HBG expression in a dose-dependent manner. Overexpression of BCL2L1 in these cells increased HBG expression fourfold (P < .05) and increased F cells by 13% (P < .05). Overexpression of BCL2L1 in erythroid progenitors derived from primary adult CD34+ cells upregulated HBG expression 11-fold (P < .05), increased F cells by 18% (P < .01), did not significantly affect cell differentiation or proliferation, and had a minor effect on survival. Although the mechanism remains unknown, our results suggest that BCL2L1 is associated with HbF gene activation.